J Pharm Technol 2022 Apr 26;38(2):119-126. Epub 2022 Jan 26.
Bon Secours Mercy Health St. Vincent Medical Center, Toledo, OH, USA.
Objective: The purpose of this review is to discuss the existing literature regarding patients who have experienced seizures after administration of a bone density conservation agent (BDCA).
Data Sources: A comprehensive literature review was performed between September and October 2021 using the following keywords: osteoporosis/drug therapy, seizures/chemically induced, hypercalcemia, hypocalcemia, osteoporosis, seizure risk, osteoclast medication, seizures, bisphosphonates, risedronate, zoledronic acid, pamidronate, denosumab, Prolia, Xgeva, calcitonin, BDCAs.
Study Selection And Data Extraction: A total of 90 articles were identified, but only 6 articles met prespecified inclusion and exclusion criteria. Read More